Articlehybrid2020

Strategies to achieve fairer prices for generic and biosimilar medicines

Alessandra Ferrario · Guillaume Dedet · Tifenn Humbert · Sabine Vogler · Fátima Suleman · Hanne Bak Pedersen

64 citations0/0 files storedBMJ

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Pharmaceutical Economics and Policy Health Systems, Economic Evaluations, Quality of Life Biosimilars and Bioanalytical Methods

Abstract

Early market entry and rapid uptake of quality assured generic and biosimilars are key to improving access to medicines, say Alessandra Ferrario and colleagues

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 64 citations exist upstream.

References

2024Two new Later Stone Age sites from the Final Pleistocene in the Falémé Valley, eastern Senegal 2017Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending 2013The economics of biosimilars.2006Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2015Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review 2015What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs 2013The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use 2008Competition in off-patent drug markets: Issues, regulation and evidence

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.